FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367595703> ?p ?o ?g. }

• W4367595703 endingPage "413" @default.
• W4367595703 startingPage "403" @default.
• W4367595703 abstract "People with substance use disorder have a high risk of SARS-CoV-2 infection and subsequent poor outcomes. Few studies have evaluated COVID-19 vaccine effectiveness among people with substance use disorder. We aimed to estimate the vaccine effectiveness of BNT162b2 (Fosun-BioNTech) and CoronaVac (Sinovac) against SARS-CoV-2 omicron (B.1.1.529) infection and related hospital admission in this population.We did a matched case-control study using electronic health databases in Hong Kong. Individuals diagnosed with substance use disorder between Jan 1, 2016, and Jan 1, 2022, were identified. People aged 18 years and older with SARS-CoV-2 infection from Jan 1 to May 31, 2022, and people with COVID-19-related hospital admission from Feb 16 to May 31, 2022, were included as cases and were matched by age, sex, and previous clinical history with controls from all individuals diagnosed with substance use disorder who attended the Hospital Authority health services: up to three controls for SARS-CoV-2 infection and up to ten controls for hospital admission. Conditional logistical regression was used to evaluate the association between vaccination status (ie, one, two, or three doses of BNT162b2 or CoronaVac) and the risk of SARS-CoV-2 infection and COVID-19-related hospital admission, adjusted for baseline comorbidities and medication use.Among 57 674 individuals with substance use disorder, 9523 people with SARS-CoV-2 infections (mean age 61·00 years, SD 14·90; 8075 [84·8%] males and 1448 [15·2%] females) were identified and matched to 28 217 controls (mean age 60·99 years, 14·67; 24 006 [85·1%] males and 4211 [14·9%] females), and 843 people with COVID-19-related hospital admissions (mean age 70·48 years, SD 14·68; 754 [89·4%] males and 89 [10·6%] females) were identified and matched to 7459 controls (mean age 70·24 years, 13·87; 6837 [91·7%] males and 622 [8·3%] females). Data on ethnicity were not available. We observed significant vaccine effectiveness against SARS-CoV-2 infection for two-dose BNT162b2 vaccination (20·7%, 95% CI 14·0-27·0, p<0·0001) and three-dose vaccination (all BNT162b2 41·5%, 34·4-47·8, p<0·0001; all CoronaVac 13·6%, 5·4-21·0, p=0·0015; BNT162b2 booster after two-dose CoronaVac 31·3%, 19·8-41·1, p<0·0001), but not for one dose of either vaccine or two doses of CoronaVac. Significant vaccine effectiveness against COVID-19-related hospital admission was detected after one dose of BNT162b2 vaccination (35·7%, 3·8-57·1, p=0·032), two-dose vaccination (both BNT162b2 73·3%, 64·3 to 80·0, p<0·0001; both CoronaVac 59·9%, 50·2-67·7, p<0·0001), and three-dose vaccination (all BNT162b2 86·3%, 75·6-92·3, p<0·0001; all CoronaVac 73·5% 61·0-81·9, p<0·0001; BNT162b2 booster after two-dose CoronaVac 83·7%, 64·6-92·5, p<0·0001), but not after one dose of CoronaVac.For both BNT162b2 and CoronaVac, two-dose or three-dose vaccination was protective against COVID-19-related hospital admission and the booster dose provided protection against SARS-CoV-2 infection among people with substance use disorder. Our findings confirm the importance of booster doses in this population during the period dominated by the omicron variant.Health Bureau, the Government of the Hong Kong Special Administrative Region." @default.
• W4367595703 created "2023-05-02" @default.
• W4367595703 creator A5003358736 @default.
• W4367595703 creator A5004488408 @default.
• W4367595703 creator A5008845183 @default.
• W4367595703 creator A5011925754 @default.
• W4367595703 creator A5016334509 @default.
• W4367595703 creator A5027126143 @default.
• W4367595703 creator A5033684035 @default.
• W4367595703 creator A5035152212 @default.
• W4367595703 creator A5037674300 @default.
• W4367595703 creator A5039196433 @default.
• W4367595703 creator A5043051253 @default.
• W4367595703 creator A5044693410 @default.
• W4367595703 creator A5047114102 @default.
• W4367595703 creator A5049875123 @default.
• W4367595703 creator A5052884442 @default.
• W4367595703 creator A5054006971 @default.
• W4367595703 creator A5066384550 @default.
• W4367595703 creator A5070343806 @default.
• W4367595703 creator A5082409466 @default.
• W4367595703 creator A5084295236 @default.
• W4367595703 creator A5090788920 @default.
• W4367595703 date "2023-06-01" @default.
• W4367595703 modified "2023-10-02" @default.
• W4367595703 title "Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study" @default.
• W4367595703 cites W2108654808 @default.
• W4367595703 cites W2114046459 @default.
• W4367595703 cites W3041497815 @default.
• W4367595703 cites W3086642606 @default.
• W4367595703 cites W3120079690 @default.
• W4367595703 cites W3161308067 @default.
• W4367595703 cites W3193761537 @default.
• W4367595703 cites W3203166542 @default.
• W4367595703 cites W3204211664 @default.
• W4367595703 cites W3209412723 @default.
• W4367595703 cites W3213552396 @default.
• W4367595703 cites W4210844692 @default.
• W4367595703 cites W4221072241 @default.
• W4367595703 cites W4223919269 @default.
• W4367595703 cites W4225657294 @default.
• W4367595703 cites W4226246286 @default.
• W4367595703 cites W4281764065 @default.
• W4367595703 cites W4285606826 @default.
• W4367595703 cites W4292210118 @default.
• W4367595703 cites W4292265393 @default.
• W4367595703 cites W4294916264 @default.
• W4367595703 cites W4294958301 @default.
• W4367595703 cites W4295102768 @default.
• W4367595703 cites W4297997530 @default.
• W4367595703 cites W4306403915 @default.
• W4367595703 cites W4309312605 @default.
• W4367595703 cites W4309698067 @default.
• W4367595703 cites W4311767501 @default.
• W4367595703 doi "https://doi.org/10.1016/s2215-0366(23)00111-6" @default.
• W4367595703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37141907" @default.
• W4367595703 hasPublicationYear "2023" @default.
• W4367595703 type Work @default.
• W4367595703 citedByCount "1" @default.
• W4367595703 countsByYear W43675957032023 @default.
• W4367595703 crossrefType "journal-article" @default.
• W4367595703 hasAuthorship W4367595703A5003358736 @default.
• W4367595703 hasAuthorship W4367595703A5004488408 @default.
• W4367595703 hasAuthorship W4367595703A5008845183 @default.
• W4367595703 hasAuthorship W4367595703A5011925754 @default.
• W4367595703 hasAuthorship W4367595703A5016334509 @default.
• W4367595703 hasAuthorship W4367595703A5027126143 @default.
• W4367595703 hasAuthorship W4367595703A5033684035 @default.
• W4367595703 hasAuthorship W4367595703A5035152212 @default.
• W4367595703 hasAuthorship W4367595703A5037674300 @default.
• W4367595703 hasAuthorship W4367595703A5039196433 @default.
• W4367595703 hasAuthorship W4367595703A5043051253 @default.
• W4367595703 hasAuthorship W4367595703A5044693410 @default.
• W4367595703 hasAuthorship W4367595703A5047114102 @default.
• W4367595703 hasAuthorship W4367595703A5049875123 @default.
• W4367595703 hasAuthorship W4367595703A5052884442 @default.
• W4367595703 hasAuthorship W4367595703A5054006971 @default.
• W4367595703 hasAuthorship W4367595703A5066384550 @default.
• W4367595703 hasAuthorship W4367595703A5070343806 @default.
• W4367595703 hasAuthorship W4367595703A5082409466 @default.
• W4367595703 hasAuthorship W4367595703A5084295236 @default.
• W4367595703 hasAuthorship W4367595703A5090788920 @default.
• W4367595703 hasBestOaLocation W43675957031 @default.
• W4367595703 hasConcept C118552586 @default.
• W4367595703 hasConcept C126322002 @default.
• W4367595703 hasConcept C166888038 @default.
• W4367595703 hasConcept C177713679 @default.
• W4367595703 hasConcept C187212893 @default.
• W4367595703 hasConcept C203014093 @default.
• W4367595703 hasConcept C22070199 @default.
• W4367595703 hasConcept C2779134260 @default.
• W4367595703 hasConcept C2908647359 @default.
• W4367595703 hasConcept C3007834351 @default.
• W4367595703 hasConcept C3008058167 @default.
• W4367595703 hasConcept C524204448 @default.
• W4367595703 hasConcept C71924100 @default.
• W4367595703 hasConcept C99454951 @default.
• W4367595703 hasConceptScore W4367595703C118552586 @default.

• next